Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SPY002

Other · developed by Spyre Therapeutics

Phase 2 Most advanced trial
SYRE Developer
1 Registered trials

What is SPY002?

SPY002 is a drug name with no further detail in the available sources. It is studied in ulcerative colitis, an inflammatory bowel disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Spyre Therapeutics, Inc. (SYRE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07012395 Phase 2 Ulcerative Colitis Recruiting SYRE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ColitisColitis, UlcerativeInflammatory Bowel DiseasesUlcerative Colitis

More from Spyre Therapeutics

Follow SYRE, the company behind SPY002

See SYRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SYRE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.